The sale follows a pre-set trading plan and leaves the executive holding 119,763 shares amid a $2.0 billion market cap.
UroGen Pharma Ltd. (NASDAQ:URGN) Chief Medical Officer Mark Schoenberg sold 10,000 shares for $400,000 on July 9, 2026, per an SEC filing. The transaction, executed at $40.23 per share, concluded a Rule 10b5-1 plan adopted in August 2025.
The company reported $140.5 million in trailing 12-month revenue and a $133.2 million net loss. UroGen’s market capitalization stood at $2.0 billion at the time of the sale, following a significant share price increase.
Schoenberg retains 119,763 ordinary shares directly. UroGen focuses on urothelial and specialty cancer treatments, including its Zusduri formulation and RTGel technology platform.